Study: Medicare Consolidated Biosimilar Payment Codes Would Save Money

December 02, 2021

Researchers report findings that suggest a different reimbursement system for Medicare Part B biologics could lead to significantly more robust savings.

NJ Court Decision Means 3 Decades of Product Exclusivity for Enbrel
Biosimilars Roundup: November Was Dominated by Legislative and Regulatory News
Biosimilar Industry Critiques Biden's Drug Pricing Reforms
Karen van Caulil, PhD, on Biosimilar Uptake in Oncology Patient Care